Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APVO Aptevo Therapeutics	$1.96 -1.5%	$3.03	$1.72 ▼ $381.10	$1.48M	5.64	982,022 shs	87,901 shs
CFRX ContraFect	$0.05	$0.05	$0.04 ▼ $13.02	$535K	0.29	1.39 million shs	910,216 shs
NCNA NuCana	$3.11 -12.6%	$12.89	$3.05 ▼ $1,892.00	$93K	1.4	540,246 shs	548,673 shs
PBM Psyence Biomedical	$3.30 +5.8%	$5.16	$2.36 ▼ $333.06	$6.17M	0.22	695,968 shs	126,202 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APVO Aptevo Therapeutics	-3.86%	-3.40%	-34.32%	-73.82%	-99.98%
CFRX ContraFect	0.00%	0.00%	0.00%	0.00%	0.00%
NCNA NuCana	-8.01%	-24.42%	-62.68%	-55.94%	-99.82%
PBM Psyence Biomedical	-5.45%	-15.22%	-38.34%	-32.61%	-99.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APVO Aptevo Therapeutics	3.1628 of 5 stars	3.5	5.0	0.0	0.0	2.4	0.0	1.3
CFRX ContraFect	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	3.3663 of 5 stars	3.3	4.0	0.0	0.0	2.5	2.5	1.3
PBM Psyence Biomedical	1.9602 of 5 stars	0.0	5.0	0.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APVO Aptevo Therapeutics	3.00	Buy	$219,040.00	11,175,410.20% Upside
CFRX ContraFect	0.00	N/A	N/A	N/A
NCNA NuCana	2.50	Moderate Buy	$5,000.00	160,671.70% Upside
PBM Psyence Biomedical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	$8.63 per share	N/A
CFRX ContraFect	N/A	N/A	N/A	N/A	($19.92) per share	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	$267.86 per share	N/A
PBM Psyence Biomedical	N/A	N/A	$1.79 per share	1.84	$11.83 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APVO Aptevo Therapeutics	-$24.13M	N/A	0.00	N/A	N/A	N/A	-675.52%	-175.68%	11/5/2025 (Estimated)
CFRX ContraFect	-$65.15M	-$19.27	N/A	N/A	N/A	N/A	N/A	-138.70%	N/A
NCNA NuCana	-$24.28M	-$1,404.00	N/A	N/A	N/A	N/A	-319.85%	-88.55%	8/21/2025 (Estimated)
PBM Psyence Biomedical	$1.01M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CFRX, APVO, PBM, and NCNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2025	NCNA NuCana	N/A	-$0.16	N/A	-$0.16	N/A	N/A
8/11/2025	Q2 2025	APVO Aptevo Therapeutics	-$83.20	-$8.40	+$74.80	-$8.40	N/A	N/A
6/2/2025	Q1 2025	NCNA NuCana	-$2.5820	-$126.00	-$123.4180	-$0.63	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APVO Aptevo Therapeutics	N/A	N/A	N/A	N/A	N/A
CFRX ContraFect	N/A	N/A	N/A	N/A	N/A
NCNA NuCana	N/A	N/A	N/A	N/A	N/A
PBM Psyence Biomedical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APVO Aptevo Therapeutics	N/A	2.27	2.27
CFRX ContraFect	N/A	0.53	0.53
NCNA NuCana	N/A	1.25	1.25
PBM Psyence Biomedical	N/A	11.04	11.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APVO Aptevo Therapeutics	8.06%
CFRX ContraFect	7.85%
NCNA NuCana	44.00%
PBM Psyence Biomedical	77.44%

Insider Ownership

Company	Insider Ownership
APVO Aptevo Therapeutics	0.12%
CFRX ContraFect	0.62%
NCNA NuCana	31.20%
PBM Psyence Biomedical	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APVO Aptevo Therapeutics	50	756,000	755,000	Not Optionable
CFRX ContraFect	23	10.70 million	10.64 million	Not Optionable
NCNA NuCana	30	30,000	21,000	Not Optionable
PBM Psyence Biomedical	N/A	1.87 million	1.80 million	N/A

CFRX, APVO, PBM, and NCNA Headlines

Recent News About These Companies

Psyence Biomedical Ltd. (PBM) Stock Price Today - WSJ

August 5, 2025 | wsj.com

Pacific Bay Warrant Extension Not Proceeding

August 1, 2025 | newsfilecorp.comN

Psyence Biomedical stock soars after partner achieves ibogaine breakthrough

August 1, 2025 | za.investing.com

Psyence Biomedical Shares Soar 70% Following Partner’s Ibogaine Extraction Breakthrough

August 1, 2025 | msn.com

Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

July 31, 2025 | financialpost.comF

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

July 31, 2025 | globenewswire.com

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

June 25, 2025 | globenewswire.com

Psyence Biomedical regains Nasdaq compliance after reverse split

June 18, 2025 | investing.com

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

June 18, 2025 | globenewswire.com

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

June 18, 2025 | newsfilecorp.comN

Psyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

June 17, 2025 | finanznachrichten.de

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

June 17, 2025 | newsfilecorp.comN

CVS Sues Arkansas Over Law Banning PBM Ownership Of Pharmacies

May 29, 2025 | forbes.com

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 27, 2025 | newsfilecorp.comN

Psyence Biomedical Ltd. Wt

May 21, 2025 | marketwatch.com

Psyence Biomedical Advances Psilocybin Drug Development as of May 2025

May 20, 2025 | tipranks.com

Psyence Biomedical announces reverse stock split

May 2, 2025 | investing.com

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

May 1, 2025 | newsfilecorp.comN

Psyence Group consolidates its shares

April 18, 2025 | greenmarketreport.comG

Psyence BioMed gets Nasdaq notice for non-compliance

April 18, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CFRX, APVO, PBM, and NCNA Company Descriptions

Aptevo Therapeutics NASDAQ:APVO

$1.96 -0.03 (-1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$2.00 +0.04 (+2.30%)

As of 05:37 PM Eastern

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

ContraFect NASDAQ:CFRX

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

NuCana NASDAQ:NCNA

$3.11 -0.45 (-12.64%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 +0.08 (+2.41%)

As of 05:42 PM Eastern

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Psyence Biomedical NASDAQ:PBM

$3.30 +0.18 (+5.77%)

Closing price 04:00 PM Eastern

Extended Trading

$3.24 -0.05 (-1.67%)

As of 05:45 PM Eastern

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time